pubmed-article:2120270 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C0017086 | lld:lifeskim |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C0267628 | lld:lifeskim |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C1697858 | lld:lifeskim |
pubmed-article:2120270 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
pubmed-article:2120270 | pubmed:dateCreated | 1990-11-6 | lld:pubmed |
pubmed-article:2120270 | pubmed:abstractText | The data from this study indicate that cefoxitin was effective and generally well tolerated in the management of gangrenous and/or perforated appendicitis. No strong correlation was identified between in vitro susceptibility testing results and clinical outcome. | lld:pubmed |
pubmed-article:2120270 | pubmed:language | eng | lld:pubmed |
pubmed-article:2120270 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2120270 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:2120270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2120270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2120270 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2120270 | pubmed:month | Oct | lld:pubmed |
pubmed-article:2120270 | pubmed:issn | 8750-2836 | lld:pubmed |
pubmed-article:2120270 | pubmed:author | pubmed-author:FinegoldS MSM | lld:pubmed |
pubmed-article:2120270 | pubmed:author | pubmed-author:ThompsonJ EJE | lld:pubmed |
pubmed-article:2120270 | pubmed:author | pubmed-author:BaronE JEJ | lld:pubmed |
pubmed-article:2120270 | pubmed:author | pubmed-author:WexlerH MHM | lld:pubmed |
pubmed-article:2120270 | pubmed:author | pubmed-author:BennionR SRS | lld:pubmed |
pubmed-article:2120270 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2120270 | pubmed:volume | 25 Suppl 4 | lld:pubmed |
pubmed-article:2120270 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2120270 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2120270 | pubmed:pagination | 3-12 | lld:pubmed |
pubmed-article:2120270 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:meshHeading | pubmed-meshheading:2120270-... | lld:pubmed |
pubmed-article:2120270 | pubmed:year | 1990 | lld:pubmed |
pubmed-article:2120270 | pubmed:articleTitle | Gangrenous and/or perforated appendix: clinical outcome and in vitro susceptibility testing. | lld:pubmed |
pubmed-article:2120270 | pubmed:affiliation | University of California, Los Angeles. | lld:pubmed |
pubmed-article:2120270 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2120270 | pubmed:publicationType | Comparative Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2120270 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2120270 | lld:pubmed |